Abstract
The present invention relates to an antiviral composition comprising Natural Killer (NK) cells as an active ingredient and, more particularly, to a composition for preventing or treating COVID-19 virus (SARS-COV-2) infection comprising NK cells as an active ingredient and a method for culturing lymphocytes comprising anti-COVID-19 virus NK cells.
Full Text
What is claimed is:
The present invention relates to an antiviral composition comprising Natural Killer (NK) cells as an active ingredient and, more particularly, to a composition for preventing or treating COVID-19 virus (SARS-COV-2) infection comprising NK cells as an active ingredient and a method for culturing lymphocytes comprising anti-COVID-19 virus NK cells.
Timeline
Filed
03/19/2026Published
07/09/2026Granted
Not AvailableIPC Codes(8)
C07K 16/24:against cytokines, lymphokines or interferons
A61K 40/15:Natural-killer [NK] cells; Natural-killer T [NKT] cells
A61K 40/46:Viral antigens